Butyrate is a four-carbon short-chain fatty acid (SCFA) naturally produced when colonic bacteria ferment dietary fiber, particularly resistant starch and pectin. It serves as the primary fuel source for the epithelial cells lining the colon (colonocytes), supplying up to 70% of their energy needs. As both a metabolite and a signaling molecule, butyrate plays a central role in gut integrity, immune regulation, and gene expression.

Butyrate works through several complementary mechanisms: it serves as the primary energy substrate for colonocytes, fueling tight junction protein synthesis that maintains intestinal barrier integrity. It also acts as a potent histone deacetylase (HDAC) inhibitor, modulating gene expression to suppress pro-inflammatory pathways (particularly NF-κB signaling) and promote regulatory T-cell differentiation. Additionally, butyrate activates G-protein coupled receptors GPR41 and GPR43, influencing gut hormone secretion, motility, and immune cell behavior.

Oral supplementation is most common in capsule or tablet form. Enteric-coated or tributyrin softgel forms are clinically preferred as they improve delivery past the stomach. Powders exist but carry a distinctive odor (rancid butter) that limits compliance. Butyrate enemas have been used in clinical trials for distal colitis and are not typically available over the counter.

• Ulcerative Colitis
• Crohn's Disease
• Irritable Bowel Syndrome (IBS)
• Intestinal Permeability (Leaky Gut)
• Colorectal Cancer (Adjunctive / Preventive Support)
• Metabolic Syndrome
• Constipation

• Colorectal cancer risk reduction (via high-fiber/butyrate-producing dietary patterns — strong epidemiological support)
• Relapse of ulcerative colitis (adjunctive oral butyrate in remission — limited but positive RCT data)
• Gut dysbiosis-related intestinal permeability

• Resistant Starch (cooked/cooled potatoes, green bananas, legumes)
• Ghee (clarified butter)
• Butter
• High-Fiber Legumes (lentils, black beans, chickpeas)
• Whole Oats

• GI bloating and gas (especially during initial use or with high doses)
• Nausea (reported with uncoated sodium butyrate at higher doses)
• Unpleasant odor — breath or stool (inherent to butyric acid; minimized with enteric-coated or tributyrin forms)
• Loose stools or diarrhea (uncommon; typically dose-dependent)
• Mild abdominal cramping (transient, usually resolves within 1–2 weeks)

• Recommended daily: 150–600 mg/day of sodium butyrate (typical supplement range); clinical IBD trials have used up to 4,000 mg/day of oral butyrate. Tributyrin doses of 400–1,000 mg/day are increasingly used for improved colonic delivery. Butyrate enemas (clinical): 80–100 mM concentration, 60–100 mL per administration.
• Best time of day: With meals, ideally split into 2 doses (morning and evening) to maintain more consistent colonic exposure throughout the day.
• With or without food: Take with food to improve tolerance and minimize GI discomfort; food also slows transit, allowing more time for colonic delivery especially with non-enteric-coated forms.
• Time to effect: Initial gut comfort improvements: 1–2 weeks. Measurable mucosal or inflammatory improvements: 4–8 weeks. Full microbiome-related benefits may require 8–12 weeks of consistent use.
• How long to take it: No established cycling requirement. For IBD maintenance or chronic gut permeability, ongoing daily use is appropriate under practitioner guidance. For general gut health support, a 12-week course with reassessment is a reasonable starting point. Long-term use appears safe based on available data.